Chlamydia Infections Therapeutics Review and Drug Development by Companies Analyzed in H2 2017

Posted on 2017-09-29 by Mark Hub in Pharmaceuticals // 0 Comments

MARKET RESEARCH HUB

Albany, US, 2017-Sep-29 — /EPR Network/ —Chlamydia is reported as the most prevalent among the different types of sexually transmitted disease. At present, fewer than 50% of sexually active young females in the United States are screened for the presence of chlamydiae. It has been analyzed that, if left untreated, it can become pelvic inflammatory disease (PID), which is a major cause of infertility, ectopic pregnancy and chronic pelvic pain. Considering this fact, several doctors are increasing their focus on treatment of sexually transmitted diseases worldwide, which as a result boosting the Chlamydia Infection market growth. A new study, covering the descriptive pharmacological action of the therapeutics, its complete research and development history has been published to the online repository of Market Research Hub (MRH) and titled as “Chlamydia Infections- Pipeline Review Market Research Reports, H2 2017”.

Request free Sample Report: https://www.marketresearchhub.com/enquiry.php?type=S&repid=1329538

This study provides comprehensive information on the therapeutics under development for chlamydia infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. In the first part, this pipeline guide starts by presenting a detailed overview of chlamydia infections. Chlamydia infection is one of the most frequently reported bacterial infections. Chlamydia-infected females may manifest vaginal bleeding, abdominal pain, fever and frequent or painful urination. Symptoms for males include urethral inflammation, burning urination, penile discharge, swollen testicles and fever. It has been analyzed that untreated Chlamydia may lead to more serious health problems that are why it is important to get tested as early as possible.

It has been analyzed that rising demand for rapid and effective diagnostic tests and therapeutics to treat this rapidly rising patient pool is significantly contributing to the growth of the chlamydia infection therapeutics market globally. At present, treatment for the disease includes antibiotics and pain medicine. In this study, overall pipeline covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 10 and 2 respectively.

Moving further, the study offers vivid drug profiles for the pipeline products which include details such as, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. Drugs commonly used to treat chlamydia include Amoxil, Doryx, Doxycycline, Erythrocin, Floxin, Gantrisin, Trimox, Zithromax and other. Some of the major drugs analyzed in this study are Ab-03, acALY-18, Amphora, Chlamydia trachomatis vaccine, Chlamydia vaccines, PEG-2S, Peptides to Inhibit CPAF for Chlamydia Infections, Small Molecules to Block Virulence for Chlamydia Infections, ST-669, VPI-201 and solithromycin.

Browse Full Report With TOC: https://www.marketresearchhub.com/report/chlamydia-infections-pipeline-review-h2-2017-report.html

At present, major companies involved in the therapeutic development include Abera Bioscience AB, Prokarium Ltd., Lead Discovery Center GmbH, SIGA Technologies Inc., NanoBio Corp., Selecta Biosciences Inc., Vault Pharma Inc., Vaxine Pty Ltd., Evofem Inc., SATT IDF Innov SAS, Merck & Co. Inc and QureTech Bio AB. These companies are profiled along with their major and minor projects.

Enquire About this Report: https://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1329538

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of reports and analysis. MRH’s expansive collection of pharmaceutical market reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Matched content

Editor’s pick